UPTODATE: We are pleased to report that Caristo’s new imaging biomarker, the Perivascular Fat Attenuation Index (FAI™), has been featured in UpToDate’s latest chapter on Noninvasive Coronary Imaging. UpToDate is the leading evidence-based, physician-authored clinical decision support resource that is used by over 1.3 million clinicians in 187 countries.
The article referenced our original Science Translational Medicine
paper from 2017 as well as the landmark CRISP-CT
trial, published in the Lancet in August 2018. The authors noted that, "In patients with suspected angina, coronary inflammation, estimated on CT with attenuation measurements of the perivascular fat, may be a predictor of poor patient outcome. In a retrospective analysis of two prospectively acquired CCTA databases with 1872 and 2040 participants in the derivation and validation cohorts, respectively, a pericoronary fat attenuation index (FAI™) of ≥-70.1 Hounsfield units, measured around the right coronary artery, was independently associated with all-cause mortality (hazard ratio [HR] 1.5, 95% CI 1.2–1.9 in the derivation cohort; 1.8, 95% CI 1.5–2.3 in the validation cohort) and cardiac mortality (HR 2.2, 95% CI 1.3–3.5 in the derivation cohort; 2.1, 1.5–2.8 in the validation cohort)."
Caristo looks forward to working with clinicians to bring this new technology to the forefront of cardiovascular medicine very soon.
Click here to read more.